Promising cancer combo trial halted after just 7 patients
NCT ID NCT05921760
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a three-drug combination (ivosidenib, nivolumab, and ipilimumab) in 7 people with advanced bile duct cancer that has a specific IDH1 mutation. The goal was to check safety and find the right dose, but the study was stopped early by the sponsor before it could test how well the treatment works. Only safety information is available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivosidenib, nivolumab, and ipilimumab
- What this could lead to
- If it had succeeded, this combination could have pointed toward a new treatment option for a rare bile duct cancer with a specific gene mutation.
- What could go wrong
- The trial was terminated early after only 7 participants, so we have very little data. The combination may cause serious side effects, and it is unclear if it would work at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1-MUTANT CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, 21231, United States
-
UCLH
London, NW1 2PG, United Kingdom
-
UCSF - Medical Center at Mission Bay
San Francisco, California, 94158, United States
-
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States